Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Remibrutinib - Novartis

Drug Profile

Remibrutinib - Novartis

Alternative Names: LOU-064

Latest Information Update: 03 Dec 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis
  • Class Anti-inflammatories; Antiasthmatics; Benzamides; Pyrimidines; Skin disorder therapies; Small molecules
  • Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Asthma; Sjogren's syndrome; Urticaria
  • Phase I Atopic dermatitis

Most Recent Events

  • 03 Dec 2020 Chemical structure information added
  • 07 May 2020 Novartis suspends a phase II trial in Urticaria in Argentina, Germany, France, Denmark, Czechia, Canada, Belgium, Turkey, Spain, Slovakia, Russia, Poland, Netherlands, Japan, Hungary, USA and United Kingdom (PO) due to COVID-19 global pandemic (NCT03926611)
  • 27 Apr 2020 Novartis terminates a phase II trial for Asthma in USA, Russia, Poland, Germany, Argentina (PO) (NCT03944707) (EudraCT2018-003609-24)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top